Printer Friendly

BIOMIRA INC. ANNOUNCES NASDAQ LISTING

 BIOMIRA INC. ANNOUNCES NASDAQ LISTING
 EDMONTON, Alberta, Nov. 8 /PRNewswire/ - Biomira Inc.


(Toronto, Montreal, Alberta: BRA) announced today that its presently outstanding common shares have been approved for quotation in the United States on the National Market System (NMS) of the National Association of Securities Dealers Automated Quotation System (NASDAQ) under the symbol "BIOMF." Trading on NASDAQ (NMS) is expected to commence no later than Nov. 19, 1991.
 Separately, it was announced that SoundView Financial Group, Inc. of Stamford Connecticut would be joining ScotiaMcLeod (USA) Inc. as an underwriter of the United States portion of Biomira's previously announced proposed cross-border public offering of approximately 4,000,000 common shares. The offering of these new common shares is expected to close during December 1991.
 The registration statement filed in the United States with the Securities and Exchange Commission with respect to the proposed new issue of common shares has not yet become effective. Accordingly these new common shares may not be sold nor may offers to buy be accepted in the United States prior to the time the registration statement becomes effective, and in Canada prior to receipts being obtained for the final prospectus from the appropriate securities commissions and other regulatory authorities. This announcement shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there by any sale of the new common shares in any Canadian province or state of the United States, in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such province or state.
 Biomira Inc., a public biotechnology company listed on the Toronto, Montreal and Alberta stock exchanges (symbol "BRA") is focused on the research, development and commercialization of cancer diagnostic and therapeutic products. Biomira currently markets four in vitro diagnostic kits for gastrointestinal, ovarian and breast cancer under the TRUQUANT label.
 -0- 11/8/91
 /CONTACT: James E. Devaney, VP-Finance, or Alex McPherson, president and chief executive officer, Biomira Inc., 403-450-3761/
 (BIOMF BRA.) CO: Biomira Inc. ST: Alberta IN: MTC SU: KJ -- LA011 -- 2600 11/08/91 12:41 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 8, 1991
Words:353
Previous Article:SANTA FE TO ACQUIRE 90 GE LOCOMOTIVES
Next Article:MARLTON TECHNOLOGIES ANNOUNCES 1991 THIRD QUARTER EARNINGS
Topics:


Related Articles
BIOMIRA ANNOUNCES COMPLETION OF PUBLIC OFFERING
BIOMIRA INC. ANNOUNCES THAT TWO OF ITS FOUNDERS SELL SMALL PORTION OF THEIR SHARES
BIOMIRA INC. ANNOUNCES REGULATORY APPROVAL FOR CLINICAL TRIALS IN GERMANY
RIBI IMMUNOCHEM LICENSES MELACINE MELANOMA THERACCINE TO BIOMIRA INC. EXCLUSIVELY IN CANADA
BIOMIRA INC. ANNOUNCES COMPLETION OF CANADIAN PUBLIC OFFERING
BIOMIRA INC. ANNOUNCES DISTRIBUTION AGREEMENT WITH AUSTRALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANISATION
BIOMIRA ANNOUNCES PLANS TO CONDUCT ADDITIONAL PHASE II CLINICAL TRIAL ON TRU-SCINT(R) AD(TM)
BIOMIRA ESTABLISHES SECOND LICENSE AGREEMENT WITH BEHRINGWERKE A.G.
Biomira Solidifies Patent Rights for Muc-1 Cancer Antigen
Biomira USA Signs License Agreement with Coulter

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters